LB Pharmaceuticals Inc Common Stock LBRX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T00:58:12.483Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:00:07.280436329Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T00:58:12.155540+00:00
LB Pharmaceuticals Inc Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 34.44 | 263.3% | 28.6% | |||
| 25Δ | 37.64 | 209.9% | 21.4% | |||
| 30Δ | 57.39 | 225.5% | 34.0% | 40.27 | 166.9% | 15.5% |
| 35Δ | 52.02 | 178.4% | 21.9% | 41.53 | 146.4% | 12.8% |
| 40Δ | 49.05 | 147.0% | 15.3% | 42.79 | 125.8% | 10.1% |
| 45Δ | 47.29 | 124.5% | 11.4% | 44.06 | 105.3% | 7.3% |
| 50Δ | 45.53 | 102.0% | 7.5% | 45.17 | 89.0% | 5.1% |
| 55Δ | 44.42 | 94.2% | 5.8% | 45.84 | 85.4% | 4.5% |
| 60Δ | 43.59 | 92.7% | 5.0% | 46.52 | 81.8% | 3.9% |
| 65Δ | 42.75 | 91.2% | 4.2% | 47.19 | 78.1% | 3.2% |
| 70Δ | 41.92 | 89.7% | 3.4% | 47.87 | 74.5% | 2.6% |
| 75Δ | 41.09 | 88.2% | 2.6% | 48.54 | 70.9% | 1.9% |
| 80Δ | 40.25 | 86.7% | 1.8% | 49.22 | 67.2% | 1.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 34.44
- IV
- 263.3%
- B/E move
- 28.6%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 37.64
- IV
- 209.9%
- B/E move
- 21.4%
30Δ
- Pseudo strike
- 57.39
- IV
- 225.5%
- B/E move
- 34.0%
- Pseudo strike
- 40.27
- IV
- 166.9%
- B/E move
- 15.5%
35Δ
- Pseudo strike
- 52.02
- IV
- 178.4%
- B/E move
- 21.9%
- Pseudo strike
- 41.53
- IV
- 146.4%
- B/E move
- 12.8%
40Δ
- Pseudo strike
- 49.05
- IV
- 147.0%
- B/E move
- 15.3%
- Pseudo strike
- 42.79
- IV
- 125.8%
- B/E move
- 10.1%
45Δ
- Pseudo strike
- 47.29
- IV
- 124.5%
- B/E move
- 11.4%
- Pseudo strike
- 44.06
- IV
- 105.3%
- B/E move
- 7.3%
50Δ
- Pseudo strike
- 45.53
- IV
- 102.0%
- B/E move
- 7.5%
- Pseudo strike
- 45.17
- IV
- 89.0%
- B/E move
- 5.1%
55Δ
- Pseudo strike
- 44.42
- IV
- 94.2%
- B/E move
- 5.8%
- Pseudo strike
- 45.84
- IV
- 85.4%
- B/E move
- 4.5%
60Δ
- Pseudo strike
- 43.59
- IV
- 92.7%
- B/E move
- 5.0%
- Pseudo strike
- 46.52
- IV
- 81.8%
- B/E move
- 3.9%
65Δ
- Pseudo strike
- 42.75
- IV
- 91.2%
- B/E move
- 4.2%
- Pseudo strike
- 47.19
- IV
- 78.1%
- B/E move
- 3.2%
70Δ
- Pseudo strike
- 41.92
- IV
- 89.7%
- B/E move
- 3.4%
- Pseudo strike
- 47.87
- IV
- 74.5%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 41.09
- IV
- 88.2%
- B/E move
- 2.6%
- Pseudo strike
- 48.54
- IV
- 70.9%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- 40.25
- IV
- 86.7%
- B/E move
- 1.8%
- Pseudo strike
- 49.22
- IV
- 67.2%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 72.79% | |
| 75.04% | |
| 72.31% | |
| 75.42% | |
| 73.73% | |
| 76.24% | |
| 78.28% | |
| 75.83% | |
| 76.79% | |
| 76.49% |
Biotechnology
LCTX
Description unavailable
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →LENZ
LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders, specifically targeting critical…
More →LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs…
More →LITS
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San…
More →LKFT
Lakefront Biotherapeutics NV (LKFT) is an innovative biopharmaceutical company focused on addressing significant unmet medical needs in oncology and infectious diseases through…
More →